Anebulo Pharmaceuticals, Inc. (ANEB)

NASDAQ: ANEB · Real-Time Price · USD

1.550

+0.080 (5.44%)

Jun 18, 2025, 4:00 PM - Market closed

Anebulo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Selling, General & Admin	4.59	4.76	6.18	3.87	1.34	0.14
Research & Development	3.64	3.55	5.6	2.96	2.27	0.9
Operating Expenses	8.23	8.31	11.78	6.83	3.61	1.04
Operating Income	-8.23	-8.31	-11.78	-6.83	-3.61	-1.04
Interest Expense	-0.42	-0.15	-	-	-0.01	-0.01
Interest & Investment Income	0.19	0.25	0.09	0.01	0	-
Other Non Operating Income (Expenses)	0.78	0.01	-0.04	-0	-26.63	-
Pretax Income	-7.69	-8.2	-11.73	-6.83	-30.25	-1.05
Net Income	-7.69	-8.2	-11.73	-6.83	-30.25	-1.05
Preferred Dividends & Other Adjustments	-	-	-	-	8.21	-
Net Income to Common	-7.69	-8.2	-11.73	-6.83	-38.46	-1.05
Shares Outstanding (Basic)	30	26	25	23	14	12
Shares Outstanding (Diluted)	30	26	25	23	14	12
Shares Change (YoY)	16.67%	2.98%	7.41%	71.49%	13.44%	-
EPS (Basic)	-0.26	-0.32	-0.47	-0.29	-2.83	-0.09
EPS (Diluted)	-0.26	-0.32	-0.47	-0.29	-2.83	-0.09
EBIT	-8.23	-8.31	-11.78	-6.83	-3.61	-1.04

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q